Company: ANTX
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0000950170-25-052852
Chunk: 14

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 14
---
 2016 to 2020, Ms. FitzPatrick served as Chief Corporate Affairs Officer for Exelon, a Fortune 200 clean energy provider. From 2013 to 2016, she served as Chief Communications Officer and VP of Public Affairs at Johnson & Johnson. From 2010 to 2013, Ms. FitzPatrick served as Chief Communications Officer and President of the Foundation at Cigna. Prior to that, Ms. FitzPatrick held multiple positions at APCO Worldwide, a global public affairs and strategic communications consultancy, including Executive Vice President. Ms. FitzPatrick is Chair of the board of directors at VistaGen Therapeutics, a Nasdaq listed, late-stage central nervous system-focused biopharmaceutical company. Ms. FitzPatrick holds a B.A. in English and Public Policy from Syracuse University and a M.A. in Public Policy from The George Washington University. She completed the board directorship program at the Harvard Business School and is certified as a corporate director by the National Association of Corporate Directors. We believe that Ms. FitzPatrick's extensive expertise in corporate governance and extensive c-suite experience at healthcare companies make her an appropriate member of our Board.

Gilbert Lynn Marks, M.D.,has served as a member of our Board since February 2020. Since 2023, Dr. Marks has served as a Special Government Employee (“SGE”) as a voting member of the Presidential Advisory Council for Combating Antibiotic-Resistant Bacteria (“PACCARB”). From 2017 to 2021, Dr. Marks was employed by Tunnell Government Services (“TGS”), a subsidiary of Tunnell Consulting, Inc. that supports clients in medical product development, and served in various positions, including most recently as Vice President. As an employee of TGS, Dr. Marks served as a contractor supporting the Office of the Director for the Biomedical Advanced Research and Development Authority (“BARDA”), a U.S. Department of Health and Human Services office responsible for the procurement and development of medical countermeasures for chemical, biological, radiological, nuclear and pandemic threats. Subsequently, from 2023 to 2024, he served as an independent contractor for TGS and supported the Influenza and Emerging Infectious Diseases team within BARDA. From 2016 to 2021, Dr. Marks served as an SGE as a member of the Advisory Committee for the National Center for Advancing Translational Sciences (“NCATS”), an institute at the National Institutes of Health. As part of